KLOW is an 80 mg single-vial peptide blend injected under the skin to rebuild collagen, firmness, and texture. It carries four peptides: GHK-Cu, BPC-157, full-length TB-4, and KPV. The first three are the same base as GLOW. The fourth, KPV, is what makes KLOW its own thing — a small anti-inflammatory peptide that keeps the inflammation switch (NF-kB¹) from interfering while the other three rebuild.
No FDA-approved KLOW blend exists, and no trial has tested the four peptides together. The evidence is per-compound, and it is uneven: decades of dermatology and gene-expression work behind GHK-Cu, a large preclinical base plus early human trials for BPC-157, and thinner human data for injectable KPV. The practical risks are vial identity, sterility, and getting the reconstitution math right — not the biology.
Pick KLOW over GLOW when inflammation is part of the skin picture: rosacea, post-procedure redness, reactive or flushing-prone baselines. For a tendon or soft-tissue injury, the cosmetic ratios underdose the repair compounds — the KLOW Dosage Calculator carries the injury-anchor math and the restructured ratios.
| At a Glance | |
|---|---|
| What it is | 80 mg four-peptide blend (GHK-Cu, BPC-157, TB-4, KPV) for subcutaneous skin repair |
| KLOW dosage | 2 mg GHK-Cu anchor per dose, plus 400 mcg each of BPC-157, TB-4, and KPV. Reconstitution math on the calculator. |
| Protocol | Daily weeks 1-4, 5x weekly weeks 5-8, then 2-3x weekly maintenance |
| Best for | Reactive skin, rosacea, post-procedure recovery, inflammatory acne — plus the firmness and texture work GLOW does |
| Results timeline | Redness down in 1-2 weeks; texture by 2-4; fine lines by 4-8; firmer structure by 8-12 |
| Side effects | Mild injection-site reactions; a 30-60 second GHK-Cu sting; the solution is naturally blue |
| Regulatory status | No FDA-approved KLOW blend. The real concerns are vial identity, sterility, and dose math. |
What Is in KLOW
KLOW is 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-4 10 mg, and KPV 10 mg. GHK-Cu carries most of the mass because collagen synthesis is the continuous daily demand. The other three work at lower doses because their effective concentrations are lower, not because they matter less.
| Component | Amount | Role |
|---|---|---|
| GHK-Cu | 50 mg | Collagen synthesis, gene regulation, antioxidant defense |
| BPC-157 | 10 mg | Capillary network, tissue-barrier stabilization |
| TB-4 | 10 mg | Cell migration, tissue organization, anti-scarring signaling |
| KPV | 10 mg | Inflammation control — blocks the master inflammatory switch, shifts immune cells toward repair |
"KLOW blend" and "KLOW stack" both refer to this same four-peptide single-vial composition. Some peptide vocabularies reserve "stack" for multi-vial protocols and "blend" for a premixed vial; for KLOW the two terms point to the same thing.
The 50/10/10/10 split is built for cosmetic use. For injury work the cocktail-tied math does not hold; the KLOW Dosage Calculator carries the injury-anchor ratios and what to restructure.
KLOW vs GLOW: Which One to Pick
KLOW is GLOW plus one peptide. Both share GHK-Cu, BPC-157, and full-length TB-4 at identical masses, so they handle collagen quality, microvascular support, and organized cell migration the same way. KLOW adds KPV, which pre-empts the inflammation switch (NF-kB¹) before it fires.
| Compare | GLOW | KLOW |
|---|---|---|
| Peptides | GHK-Cu + BPC-157 + TB-4 | GHK-Cu + BPC-157 + TB-4 + KPV |
| Total mass | 70 mg | 80 mg |
| Best for | Firmness, texture, fine lines, scar remodeling | The same, plus reactive skin, rosacea, post-procedure |
| Dosing | 2 mg GHK-Cu anchor, phased schedule | Identical |
Pick GLOW when baseline skin is calm and the goal is aging, fine lines, firmness, or hair-growth support. Pick KLOW when inflammation is interfering — active rosacea, post-laser or post-microneedling recovery, inflammatory acne, chronic low-grade facial redness.
Both reconstitute the same way and run the same schedule, so switching mid-cycle is a vial swap with no change to the math. Some users run KLOW during active flares and GLOW during stable stretches. Full GLOW detail lives in the GLOW Peptide Protocol.
How KLOW Works
Skin aging and skin inflammation are several systems failing at once: collagen genes firing less, the capillary supply thinning, repair cells losing coordination, and inflammatory tone interfering with all of it. KLOW assigns one peptide to each bottleneck. KPV is the piece GLOW lacks, so it leads here.
KPV: inflammation control
KPV is a three-amino-acid fragment of alpha-MSH, a natural anti-inflammatory hormone. It stops inflammatory genes from switching on in the first place (NF-kB inhibition¹), which is a different approach from NSAIDs that block inflammation after it has already started. Normal immune signaling needed for healing stays intact.
On reactive skin, that means redness and flushing settle before the slower collagen work surfaces. Most users notice baseline redness drop in the first one to two weeks. KPV's strongest preclinical evidence is for oral delivery to gut tissue, where inflamed cells actively absorb it²; subcutaneous KLOW distributes it systemically instead, which suits skin-local inflammation but has not been tested in controlled human trials for blends like this.
GHK-Cu: collagen and structure
GHK-Cu is a copper-binding tripeptide mapped across more than 4,000 genes: collagen synthesis, antioxidant defense, and wound-healing programs trend up; inflammation and tissue-breakdown programs trend down³. Circulating levels fall with age, from roughly 200 ng/mL at 20 to about 80 ng/mL by 60. It both clears damaged matrix and lays down replacement collagen, where most collagen interventions only do the second. The copper it carries is also why the solution is blue and why a fresh dose stings briefly.
BPC-157: blood supply
BPC-157 is a 15-amino-acid fragment from gastric juice. It builds the capillary network active regeneration depends on (new blood vessel formation⁴) and stabilizes tissue barriers so new tissue holds together. Without blood flow to the dermis, GHK-Cu has the signal but the raw material never reaches the work.
TB-4: cell migration
Full-length thymosin beta-4 (43 amino acids) governs how repair cells move into and organize inside tissue⁵. It biases healing toward functional tissue rather than rope-like scarring and helps inflammation resolve cleanly. KLOW uses the full-length parent, not the shorter TB-500 fragment sold for injury work — the two get blurred on labels routinely⁶, so vial identity matters.
KLOW Dosage
Each KLOW dose anchors on 2 mg GHK-Cu and delivers 400 mcg each of BPC-157, TB-4, and KPV. The schedule changes the frequency across three phases, never the per-dose amount.
KLOW dosage chart
| Compound | Per dose | Phase 1 (wks 1-4) | Phase 2 (wks 5-8) | Phase 3 (wks 9+) |
|---|---|---|---|---|
| GHK-Cu | 2 mg | Daily | 5x/week | 2-3x weekly |
| BPC-157 | 400 mcg | Daily | 5x/week | 2-3x weekly |
| TB-4 | 400 mcg | Daily | 5x/week | 2-3x weekly |
| KPV | 400 mcg | Daily | 5x/week | 2-3x weekly |
The reconstitution math — bacteriostatic water volume, the syringe draw for your vial size, and any custom anchor — lives on the KLOW Dosage Calculator, which also carries the injury-anchor ratios. General syringe handling is in the Reconstitution Guide.
KLOW Protocol: Three-Phase Schedule
The mixture never changes across the protocol — only the frequency does. The per-injection dose holds at 2 mg GHK-Cu through every phase.
Phase 1: activation (weeks 1-4)
Daily dosing. GHK-Cu switches on collagen production and supplies the copper for proper cross-linking. BPC-157 builds the small-vessel supply that feeds active tissue. TB-4 mobilizes repair cells. KPV suppresses the inflammatory interference the whole time. Expect hydration and tone to improve, texture to soften, and redness to drop — the redness change is usually the first thing KLOW users see.
Phase 2: remodeling (weeks 5-8)
Five times weekly, same per-dose amount. All four peptides run at peak coordinated activity. GHK-Cu drives maximum collagen and elastin output; small dermatology studies report meaningful gains in collagen synthesis and reductions in wrinkle depth over 8-12 weeks³. Fine lines soften, elasticity improves, skin thickness increases.
Phase 3: maintenance (weeks 9+)
Two or three times weekly. Newly synthesized collagen needs 48-72 hours between pulses to organize and cross-link, so a pulsed cadence holds results without the constant pressure of daily dosing. Run it ongoing, or return to a 4-week daily intensive every three to four months.
A standard cycle is 12 weeks active, then a step down to maintenance or 4-8 weeks off. Indefinite daily dosing is not the default — no long-term human data exists for the blend, so a cadence is the conservative choice.
Timeline: What to Expect
| Week | What is happening | What you notice |
|---|---|---|
| 1-2 | Inflammation switch quieting, vascular network forming | Redness and flushing drop, skin calmer |
| 2-4 | Collagen gene activation, hydration | Smoother texture, more even tone |
| 4-8 | Peak collagen synthesis, organized migration | Fine lines soften, elasticity returns |
| 8-12 | Matrix remodeling and integration | Firmer structure, scar remodeling, visible density |
Baseline week-0 photos are the cleanest way to track this, since gradual change is hard to register day to day.
Supporting Factors
| Component | Target | Why |
|---|---|---|
| Protein | At least 1.6 g/kg daily | Raw material for tissue synthesis |
| Vitamin C | 500-1,000 mg daily | Collagen cross-linking cofactor |
| Hydration | 2-3 L daily | Matrix hydration |
| Zinc | 15-25 mg if supplementing copper | Copper-zinc balance |
| Sleep | 7-9 hours | Collagen synthesis peaks in deep sleep |
When Progress Stalls
Read the stall pattern instead of pushing the dose harder.
- Plateau at week 4-6 with clean execution. The architectural work has hit its energy envelope. Add NAD+ or tighten recovery support; do not escalate KLOW.
- Inflammation persists past week 6 on KLOW. The driver may be mast-cell-mediated or systemic rather than NF-kB-local. Consider mast-cell-targeted work or a clinical workup; dose escalation will not reach it.
- Weak results across the board. Usually substrate shortage. Check the protein floor, vitamin C, copper-zinc balance, reconstitution and storage technique, and sleep before adding compounds.
- Skin calms but gut symptoms remain. Subcutaneous KLOW does not reach the gut surface. KPV's gut work is oral, through the PepT1 transporter²; treat the gut as a separate route and problem.
Safety and Contraindications
Do not use KLOW with active malignancy or a cancer history under five years (GHK-Cu, BPC-157, and TB-4 promote new blood vessel formation), with Wilson's disease or copper-metabolism disorders (GHK-Cu), during pregnancy or breastfeeding, within two weeks of major surgery, or with a known allergy to any component.
Side effects are uncommon and usually mild: injection-site redness or slight swelling, the GHK-Cu sting, transient warmth or flushing, occasional mild fatigue. Persistent hives, swelling, throat tightness, or breathing changes are not a normal peptide flush and warrant stopping and seeking care.
No long-term human data exists for KLOW as a blend, so indefinite daily use is not the default. The hard contraindications above apply at any duration.
What Evidence Exists
| Compound | Evidence base |
|---|---|
| GHK-Cu | Split-face human dermatology trials on wrinkle depth and skin density (n usually under 50 per arm); microarray gene mapping (4,000+ genes); decades of cosmetic and wound-healing literature. No multi-center RCT. |
| BPC-157 | 100+ preclinical studies in injury, GI, and tendon models; small early human trials (2024-2025) on tendon and gut. No published Phase 3. |
| TB-4 | Preclinical wound-healing data; Phase 2/3 ophthalmic trials in corneal healing; cosmetic dosing extrapolated from injury models. |
| KPV | Mechanistic NF-kB data; small clinical trials in IBD (oral) and atopic dermatitis (topical/oral). No published subcutaneous human data for systemic effects. |
No controlled trial has evaluated KLOW as a blend. Synergy is inferred from the individual mechanisms, not demonstrated in combination.
FAQ
What is the difference between KLOW and GLOW?
KLOW is GLOW plus a fourth peptide, KPV, which pre-empts the inflammation switch (NF-kB) before it activates. The shared three (GHK-Cu, BPC-157, and full-length TB-4) handle collagen quality, blood supply, and cell migration in both. Use GLOW when skin is calm; use KLOW when inflammation is part of the picture. Same dosing math, so switching mid-cycle is a vial swap.
Is KLOW good for rosacea?
KLOW is the rosacea-baseline pick in this family. The inflammation switch (NF-kB) drives the flushing and reactive flares that define rosacea, and KPV pre-empts that activation rather than blocking it after it fires. Most users see baseline redness drop in the first one to two weeks, before the collagen work surfaces at weeks 4-8. If symptoms persist past week 6, the driver is more likely mast-cell-mediated, and dose-escalating KLOW will not help.
What are the benefits of KLOW?
KLOW pairs collagen rebuilding with active inflammation control, which is what sets it apart from a plain skincare blend. GHK-Cu activates collagen genes and supplies the copper cofactor for cross-linking; BPC-157 builds the capillary supply that feeds the work; full-length TB-4 organizes repair cells with an anti-scarring bias; KPV keeps the inflammation switch from interfering. Practical readouts: redness down in 1-2 weeks, texture by 2-4, fine lines by 4-8, firmer structure and scar remodeling by 8-12.
What are the side effects of KLOW?
The most common is a 30-60 second sting from GHK-Cu's copper content, which fades quickly and is not a sign of contamination. Others are mild and uncommon: injection-site redness or swelling, transient warmth or flushing, occasional mild fatigue. Persistent hives, swelling, throat tightness, or breathing changes are not a normal flush — stop and seek care.
How long does a KLOW cycle run?
Twelve weeks active is standard: daily for weeks 1-4, five times weekly for weeks 5-8, then 2-3 times weekly through week 12. After that, step down to maintenance or take 4-8 weeks off. Indefinite daily dosing is not the default, because pulsed maintenance holds results without blunting the response. Some users run a 4-week daily intensive every three to four months instead of continuous maintenance.
Can you use KLOW for injuries?
Not as a blend. At the cosmetic anchor, BPC-157 lands at 400 mcg/day (short for refractory injury), the TB-4 is full-length rather than the TB-500 fragment and well below injury mass, GHK-Cu is over-rich, and NAD+ is absent. The KLOW Dosage Calculator carries the injury-anchor ratios and the restructured dose math; the Wolverine Stack is the full injury protocol.
Can you make KLOW from separate vials?
Yes. Buy GHK-Cu, BPC-157, full-length TB-4, and KPV individually, then reconstitute together or run separate injections. Individual vials are usually cheaper per mg but mean four cold-chain items, more sterile draws per dose, and matching the ratio yourself. A pre-mixed vial trades cost for fewer mistakes.
Can you use KLOW with GLP-1 medications?
Yes. The mechanisms do not overlap, and pairing is common during weight-loss phases. Rapid GLP-1-driven loss often outpaces the skin's ability to remodel, and KLOW supports collagen directly through the loss curve. If you are in a caloric deficit, consider adding NAD+ as the metabolic floor.
Related Topics
- GLOW Peptide Protocol — the three-peptide base, for calm skin
- GHK-Cu for Skin — GHK-Cu mechanism deep-dive
- KPV Guide — the inflammation-control peptide that defines KLOW
- KLOW Dosage Calculator — solve any anchor dose, vial size, or draw volume
- Wolverine Stack — BPC-157 + TB-500 for structural injury
- Where to Inject Peptides — injection logic for KLOW and individual compounds
- Reconstitution Guide — technique for all peptide vials
References
¹ KPV anti-inflammatory mechanism — NF-kB nuclear-import blockade, cytokine suppression, M1-to-M2 immune-cell shift; non-melanocortin-receptor mechanism distinct from the alpha-MSH parent: Luger TA, Brzoska T. Ann Rheum Dis 2007. PubMed 17921186
² KPV oral delivery via PepT1 — transporter uptake in inflamed intestinal tissue, NF-kB and MAP-kinase suppression at nanomolar concentrations, PepT1-knockout loss-of-function: Dalmasso G et al. Gastroenterology 2008. PMC2431115; Viennois E et al. Cell Mol Gastroenterol Hepatol 2016. PMC4957955
³ GHK-Cu gene modulation — COL1A1/COL3A1 collagen activation, lysyl-oxidase cross-linking, bidirectional MMP regulation, SOD/catalase antioxidant expression, 4,000+ gene modulation via microarray: Pickart L, Margolina A. Int J Mol Sci 2018. PMC6073405
⁴ BPC-157 angiogenic signaling — VEGF expression, tight-junction upregulation, capillary sprouting; rodent and dog IV PK characterization: Sikiric P et al. Curr Pharm Des 2018. PMC8275860; He L et al. Front Pharmacol 2022. PMC9794587
⁵ Thymosin beta-4 tissue repair — G-actin sequestration for cell mobility, TGF-beta anti-scarring regulation, M2 macrophage polarization: Goldstein AL et al. Trends Mol Med 2005. PubMed 16099219
⁶ TB-4 / TB-500 product mislabeling — documented bidirectional mislabeling between full-length TB-4 (43 aa, ~4,900 Da) and the TB-500 fragment (17-23, ~800 Da): Esposito M et al. Drug Test Anal 2012. PubMed 22962027